Progress of the NSCLC Revolution

Agenda

Molecular Testing in NSCLC: Where Are We Going?

The NGS Era in France

Current Molecular Testing Guidelines

Tumor Responses to Crizotinib in ROS1-Rearranged NSCLC

First-Line Dabrafenib-Trametinib in BRAF-Positive NSCLC: PFS

The Potential of Precision Medicine

Faculty Commentary NGS and Testing

Molecular Testing Workflow

Comparison of Testing Methods

Faculty Commentary: Testing and Treatments

Summary of Frontline Immunotherapy Trials

Lack of Correlation Between TMB and PD-L1

Treating New Molecular Targets in NSCLC: How Are We Progressing?

Smoking Status in Patients With Uncommon Mutations

Overview of Select cMET Inhibitors: MET Amplification as a Target

Overview of Select cMET Inhibitors: MET Exon 14 Mutations as a Target

Overview of Select ERBB2/HER2 Inhibitors: HER2 Exon 20 Mutations as a Target

Overview of Select ERBB2/HER2 Inhibitors: HER2 Amplification as a Target

Overview of Select RET Inhibitors

Other RET Inhibitors of Interest in Early Trials

Data on TRK Inhibitors

Resistance Mechanisms

Immunotherapy in NSCLC: Where Have We Got To?

Monotherapy With Immunotherapy

Combination Chemotherapy and Immunotherapy

Emerging Data From IMpower132

CheckMate 227 Trial Design

Nivolumab Combinations: CheckMate 227

Frontline Immunotherapy in EGFR-Positive Patients

Second-Line Immunotherapy in EGFR/ALK-Positive Patients

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)